Low Bowel Cancer (Colo-rectal cancer) Awareness In UK (in women)

"...In the UK, bowel cancer is the one of the top three most common cancers diagnosed in both men and women, yet nearly three quarters of the women included in the survey did not recognize the disease as being one of the three most prevalent cancers in women."

Non-Curable Tumours of the Female Genital Tract: Therapeutic Options in Bowel Stenosis and Bleeding

BACKGROUND: ......  Ovarian cancer is in particular associated with peritoneal carcinomatosis or local tumour progression entailing different intestinal complications.
.

abstract: Clinical predictors of (Avastin) bevacizumab-associated gastrointestinal perforation

Abstract

OBJECTIVES: Bevacizumab is a generally well-tolerated drug, but bevacizumab-associated gastrointestinal perforations (BAP) occur in 0 to 15% of patients with ovarian carcinoma. Our goal was to evaluate the clinical predictors of BAP in order to identify factors, which may preclude patients from receiving treatment.
METHODS: We conducted a review of patients with recurrent epithelial ovarian carcinoma treated with bevacizumab between 2006 and 2009. Demographic and treatment data were collected for statistical analysis.
RESULTS: Eighty-two patients were identified; perforation occurred in 8 (9.76%). Among patients with perforation, a significantly higher incidence of prior bowel surgeries (p=0.0008) and prior bowel obstruction or ileus.
CONCLUSIONS: Predicting BAP remains a challenge. Bowel obstruction or ileus appears to be associated with increased risk of BAP.

abstract: Prevalence of bowel symptoms in women with pelvic floor disorders

Conclusions
"Women rarely seek urogynecologic care primarily for bowel symptoms, although they have a high prevalence of bowel symptoms."

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? (Avastin)

full access:Gynaecological oncology Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer

"This is a small, single institution, retrospective study. The limitations imposed by these attributes have to be borne in mind when interpreting or using the findings of this study."